Sarepta Therapeutics Inc (SRPT)

Pretax margin

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	34,060	-520,098	-661,775	-885,019	-1,098,527	-689,963	-710,546	-502,035	-355,701	-418,948	-485,544	-634,040	-703,081	-553,065	-599,572	-529,269	-654,698	-713,880	-620,562	-571,529
Revenue (ttm)	US$ in thousands	1,403,300	1,243,336	1,104,982	1,003,434	975,683	933,013	876,047	835,184	765,786	701,887	645,564	600,082	573,356	540,099	495,074	450,191	407,496	380,833	365,135	344,580
Pretax margin		2.43%	-41.83%	-59.89%	-88.20%	-112.59%	-73.95%	-81.11%	-60.11%	-46.45%	-59.69%	-75.21%	-105.66%	-122.63%	-102.40%	-121.11%	-117.57%	-160.66%	-187.45%	-169.95%	-165.86%

March 31, 2024 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $34,060K ÷ $1,403,300K
= 2.43%

The pretax margin of Sarepta Therapeutics Inc has displayed significant fluctuations over the past, ranging from negative values indicating losses to small positive percentages. The company experienced challenges in generating consistent profitability, with margins deteriorating notably in certain periods. The pretax margin reached its lowest point at -187.45% in December 2019, indicating substantial losses relative to its revenue before tax. Despite this, there have been occasional improvements in profitability, such as the pretax margin of 2.43% in March 2024, suggesting a modest level of profitability. Overall, the trend in Sarepta Therapeutics Inc's pretax margin underscores the company's volatility in achieving profitability, requiring close monitoring and potentially strategic adjustments to enhance financial performance.